Mpox, HIV infection, and genital skin disease: triple burden, threats and challenges from an epidemiological perspective
DOI:
https://doi.org/10.70347/svsthya.v1i1.1Keywords:
Triple burden, Infectious diseases, Epidemiology, Mpox, HIV, STIsAbstract
The expansion and transformation of Mpox (MPX) disease alongside HIV and genital skin diseases has led to an increase in global morbidity and mortality in a relatively brief period. These diseases have a similar transmission pathway through sexual intercourse (mainly MSM/men-sex with males). This review aims to provide a concise, evidence-based overview of MPX, HIV, and genital skin disease coinfections, and to identify epidemiological threats and challenges. Our investigations revealed that from January 2022 to July 2023, there was a significant increase in the number of MPX cases, which reached a total of 88,600, resulting in 152 deaths across 113 countries. There have been case reports of triple-burden disease in six different areas of the world, with at least 52% of reported cases occurring in men who have had sexual activity with other men, 84.1% of whom do not use condoms and do not take pre-exposure prophylaxis (PrEP). In addition, the highest number of deaths due to co-infection with MPX, HIV infection, and genital skin diseases occurred in vulnerable groups (LGBTQIA2S+), especially in men who had sex with men, up to 90.9%, and experienced an increase in the frequency of triple burden diseases to 104.9%. From an epidemiological standpoint, this condition generates several threats and challenges, including an increasing burden of infectious diseases, an increase in immunocompromised populations, an increase in overlapping risk factors, diagnostic difficulties, an increase in interactions and comorbidities, and relatively complex treatment challenges. To suppress these outbreaks and pandemics, comprehensive control and prevention should be proposed collaboratively, including collaboration with the education sector to conduct better research and investigation using one health in complex settings. Epidemiological modeling can be used in the future to accelerate the control of these diseases.
Downloads
References
CDC. Mpox Outbreak Global Map. Centers for Disease Control and Prevention 2023. https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html (accessed May 9, 2023).
Adnyana IMDM. Monkeypox and genital skin diseases: New challenges from a dermatological perspective. J Pak Assoc Dermatol 2023;33:811–2. https://www.jpad.com.pk/index.php/jpad/article/view/2421
Vivancos-Gallego MJ, Sánchez-Conde M, Rodríguez-Domínguez M, Fernandez-Gonzalez P, Martínez-García L, Garcia-Mouronte E, et al. Human Monkeypox in people with HIV: transmission, clinical features, and outcome. Open Forum Infect Dis 2022;9:ofac557. https://doi.org/10.1093/ofid/ofac557.
Mitjà O, Alemany A, Marks M, Lezama Mora JI, Rodríguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. The Lancet 2023;401:939–49. https://doi.org/10.1016/S0140-6736(23)00273-8.
Mardani M, Pourkaveh B. Monkeypox and the prevalence of human immunodeficiency virus and other sexually transmitted infections. Arch Clin Infect Dis 2023;17:e135151. https://doi.org/10.5812/archcid-135151.
Rivera-Ruiz I, Corona-Mata D, Camacho-Espejo Á. Monkeypox infection presenting as genital lesions. Indian J Dermatol Venereol Leprol 2023:1. https://doi.org/10.25259/IJDVL_790_2022.
Scotti B, Piraccini BM, Gaspari V. Hypertrophic verrucous lesions after monkeypox virus infection. Lancet Infect Dis 2023;23:259. https://doi.org/10.1016/S1473-3099(22)00695-8.
WHO. 2022-23 Mpox (Monkeypox) outbreak: global trends. Emergency Situational Updates 2023. https://www.who.int/emergencies/situations/monkeypox-oubreak-2022
Maronese CA, Avallone G, Aromolo IF, Spigariolo CB, Quattri E, Ramoni S, et al. Mpox: an updated review of dermatological manifestations in the current outbreak. British Journal of Dermatology 2023:ljad151. https://doi.org/10.1093/bjd/ljad151.
Farahat RA, Umar TP, Khan SH, Shrestha AB, Kamran A, Essar MY, et al. Preparedness of Eastern Mediterranean countries in view of monkeypox emergence during the COVID-19 pandemic: A call for action. International Journal of Surgery 2022;105:106878. https://doi.org/10.1016/j.ijsu.2022.106878.
Farahat RA, Rackimuthu S, Umar TP, Siddiqui JA, Shrestha AB, Essar MY. Preparedness of South East Asia countries in view of monkeypox emergence: A call for action. The Lancet Regional Health - Southeast Asia 2022;6:100074. https://doi.org/10.1016/j.lansea.2022.100074.
Philpott D, Hughes CM, Alroy KA, Kerins JL, Pavlick J, Asbel L, et al. Epidemiologic and clinical characteristics of Monkeypox Cases — United States, May 17–July 22, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1018–22. https://doi.org/10.15585/mmwr.mm7132e3.
Ortiz-Saavedra B, Montes-Madariaga E, Cabanillas-Ramirez C, Alva N, Ricardo-Martínez A, León-Figueroa D, et al. Epidemiologic situation of HIV and monkeypox coinfection: A systematic review. Vaccines 2023;11:246. https://doi.org/10.3390/vaccines11020246.
Saldana CS, Kelley CF, Aldred BM, Cantos VD. Mpox and HIV: a Narrative Review. Curr HIV/AIDS Rep 2023;13:1–9. https://doi.org/10.1007/s11904-023-00661-1.
Mahase E. Mpox: Clinicians identify severe form with high mortality in advanced HIV patients. BMJ 2023;380:422. https://doi.org/10.1136/bmj.p422.
Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, et al. Monkeypox virus infection in humans across 16 Countries — April–June 2022. New England Journal of Medicine 2022;387:679–91. https://doi.org/10.1056/NEJMoa2207323.
Wang X, Lun W. Skin manifestation of human Monkeypox. J Clin Med 2023;12:914. https://doi.org/10.3390/jcm12030914.
Ciccarese G, Di Biagio A, Bruzzone B, Guadagno A, Taramasso L, Oddenino G, et al. Monkeypox outbreak in Genoa, Italy: Clinical, laboratory, histopathologic features, management, and outcome of the infected patients. J Med Virol 2023;95:28560. https://doi.org/10.1002/jmv.28560.
Jang W, Kandimalla L, Rajan S, Abreu R, Campos JE. Monkeypox in an immunocompromised patient with underlying human immunodeficiency virus and syphilis infections in Southern Florida of the United States: a case report. AIDS Res Ther 2023;20:12. https://doi.org/10.1186/s12981-023-00504-4.
Patel A, Bilinska J, Tam JCH, Da Silva Fontoura D, Mason CY, Daunt A, et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. BMJ 2022:e072410. https://doi.org/10.1136/bmj-2022-072410.
WHO. Epidemiological fact sheet HIV statistics , globally and by WHO region , 2023. HIV Data and Statistics 2023:1–8. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics (accessed July 15, 2023).
Roser M, Ritchie H. HIV / AIDS. Our World in Data 2018. https://ourworldindata.org/hiv-aids (accessed May 17, 2023).
Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, et al. Clinical characteristics of monkeypox virus infections among men with and without: A large outbreak cohort in Germany. HIV Med 2023;24:389–97. https://doi.org/10.1111/hiv.13378.
Antinori A, Mazzotta V, Vita S, Carletti F, Tacconi D, Lapini LE, et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Eurosurveillance 2022;27:pii=2200421. https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421.
Accordini S, Cordioli M, Pomari E, Tacconelli E, Castilletti C. People with asymptomatic or unrecognised infection potentially contribute to monkeypox virus transmission. Lancet Microbe 2023;4:e209. https://doi.org/10.1016/S2666-5247(22)00379-2.
Viguier C, de Kermel T, Boumaza X, Benmedjahed NS, Izopet J, Pasquier C, et al. A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: clinical and virological outcome. International Journal of Infectious Diseases 2022;125:135–7. https://doi.org/10.1016/j.ijid.2022.10.031.
Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat LA. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infect Dis 2023;23:146. https://doi.org/10.1186/s12879-023-08075-5.
O’Shea J, Daskalakis D, Brooks JT. The emergence of mpox as an HIV-related opportunistic infection. The Lancet 2023;401:1264. https://doi.org/10.1016/S0140-6736(23)00395-1.
März JW, Holm S, Biller-Andorno N. Monkeypox, stigma and public health. The Lancet Regional Health - Europe 2022;23:100536. https://doi.org/10.1016/j.lanepe.2022.100536.
Ortiz-Martínez Y, Rodríguez-Morales AJ, Franco-Paredes C, Chastain DB, Gharamti AA, Vargas Barahona L, et al. Monkeypox – a description of the clinical progression of skin lesions: a case report from Colorado, USA. Ther Adv Infect Dis 2022;9:204993612211177. https://doi.org/10.1177/20499361221117726.
Mohseni Afshar Z, Goodarzi A, Emadi SN, Miladi R, Shakoei S, Janbakhsh A, et al. A Comprehensive Review on HIV-Associated Dermatologic Manifestations: From Epidemiology to Clinical Management. Int J Microbiol 2023;2023:1–10. https://doi.org/10.1155/2023/6203193.
Turpin RE, Mandell C, Camp AD, Davidson Mhonde RR, Dyer T V., Mayer KH, et al. Monkeypox-Related Stigma and Vaccine Challenges as a Barrier to HIV Pre-Exposure Prophylaxis among Black Sexual Minority Men. Int J Environ Res Public Health 2023;20:6324. https://doi.org/10.3390/ijerph20146324.
Stewart J, Bartkus M, Sperring H, Ruiz-Mercado G, Johnson S, Pierre C. Monkeypox Vaccination Strategy and Missed Opportunities in STI and HIV Prevention: An Urban Sexual Health Clinic’s Experience During a Public Health Emergency. Open Forum Infect Dis 2023;10:ofad006. https://doi.org/10.1093/ofid/ofad006.
Pittalis S, Mazzotta V, Orchi N, Abbate I, Gagliardini R, Gennaro E, et al. Results of an interventional HIV testing programme in the context of a mpox (formerly monkeypox) vaccination campaign in Latium Region, Italy, August to October 2022. Eurosurveillance 2022;27:2200890. https://doi.org/10.2807/1560-7917.ES.2022.27.48.2200890.
Kuehn BM. Early Treatment Recommended for Patients with HIV and Monkeypox. JAMA 2022;328:2203. https://doi.org/10.1001/jama.2022.20035.
Tambo E, Al-Nazawi AM. Combating the global spread of poverty-related Monkeypox outbreaks and beyond. Infect Dis Poverty 2022;11:80. https://doi.org/10.1186/s40249-022-01004-9.
Adnyana IMDM, Utomo B, Eljatin DS, Sudaryati NLG. One Health approach and zoonotic diseases in Indonesia: Urgency of implementation and challenges. Narra J 2023;3:e257. https://doi.org/10.52225/narra.v3i3.257.
Yuan P, Tan Y, Yang L, Aruffo E, Ogden NH, Bélair J, et al. Assessing transmission risks and control strategy for monkeypox as an emerging zoonosis in a metropolitan area. J Med Virol 2023;95:28137. https://doi.org/10.1002/jmv.28137.
Mussini C, Guaraldi G, Orkin C. Monkeypox vaccination—an opportunity for HIV prevention. Lancet HIV 2022;9:e741–2. https://doi.org/10.1016/S2352-3018(22)00292-2.
Mahase E. Monkeypox: Gay and bisexual men with high exposure risk will be offered vaccine in England. BMJ 2022:o1542. https://doi.org/10.1136/bmj.o1542.
Ghaffar RA, Shahnoor S, Farooq M. Increased prevalence of HIV among Monkeypox patients – An alarming update. New Microbes New Infect 2022;49–50:101039. https://doi.org/10.1016/j.nmni.2022.101039.
Delaney KP, Sanchez T, Hannah M, Edwards OW, Carpino T, Agnew-Brune C, et al. Strategies Adopted by Gay, Bisexual, and Other Men Who Have Sex with Men to Prevent Monkeypox virus Transmission — United States, August 2022. MMWR Morb Mortal Wkly Rep 2022;71:mm7135e1. https://doi.org/10.15585/mmwr.mm7135e1.
Curran KG, Eberly K, Russell OO, Snyder RE, Phillips EK, Tang EC, et al. HIV and Sexually Transmitted Infections Among Persons with Monkeypox — Eight U.S. Jurisdictions, May 17–July 22, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1141–7. https://doi.org/10.15585/mmwr.mm7136a1.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 I Made Dwi Mertha Adnyana, Dwinka Syafira Eljatin, Sidik Maulana, Kusman Ibrahim, Tungki Pratama Umar, Luh Nik Armini, Zito Viegas da Cruz
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
